MNOV Stock Price
MediciNova, Inc.
MNOV stock price is $1.42 (-2.07% on the day), giving MediciNova, Inc. a market cap of $69.89M. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
MNOV Stock Overview
- Price
- $1.42
- Previous close
- $1.45
- Open
- $1.47
- Market cap
- $69.89M
- P/E ratio
- -5.8
- 52-week range
- $1.17 - $3.90
- 1-year price target
- $8.40
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NSD
- MarketXLS Rank
- 34
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MNOV | $1.42 | -2.1% | 79.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |